Brief: Volition Files Patent For Nu.Q(Tm) Covid-19 Triage Test And Commences Proof Of Concept Studies
April 23 (Reuters) - VolitionRX Ltd VNRX.A :
* VOLITION FILES PATENT FOR NU.Q(TM) COVID-19 TRIAGE TEST
AND
COMMENCES PROOF OF CONCEPT STUDIES
* VOLITIONRX -WORKING WITH COLLABORATORS TO INVESTIGATE IF
EXISTING NU.Q(TM) EPIGENETIC ASSAYS CAN PREDICT WHICH PATIENTS
WITH COVID-19 ARE MOST AT RISK
Source text for Eikon: ID:nPn6N5ZPZa
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems